andrewbud
Andrew Bud, CEO at iProov.

Biometric tech firm launches live testing of UK COVID-19 passport

A London-based biometric identification specialist has today announced the trial launch of its new COVID-19 immunity and vaccination passport.

iProov has partnered with deeptech firm Mvine to launch the Mvine-iProov passport, after securing £75k investment from Innovate UK.

The passport enables a person’s test result or vaccination status to be registered and proved without disclosing their identity.

Founded by Andrew Bud, iProov specialises in identification verification technology, and has previously secured contracts with the likes of the US Department of Homeland Security and the UK Home Office.

Andrew Bud, CEO at iProov, commented: “Ensuring consumer trust, security and privacy is essential to the success of projects in this space. iProov enables all three.

“Our Genuine Presence Assurance technology secures the link between the citizen and Mvine’s test status solution in this project, which we think can make an important contribution to forming the national response to the COVID-19 crisis.”

Frank Joshi, director at Mvine, added: “Without the need for an extensive new infrastructure, the Directors of Public Health will learn how our innovation is used to promote public health and protect citizen privacy.

“Unlike some other digital solutions for Covid-19, this technology reduces the burden on frontline services and cost-effectively assures a secure and safe way to enable the return to work, return to school and return to the kind of life that people want to lead.”

Our Partners